16 December 2021 
EMA/CHMP/694182/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Xevudy 
sotrovimab 
On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Xevudy, 
intended for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 
kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are 
at increased risk of progressing to severe COVID-19 (see section 5.1). The applicant for this medicinal 
product is GlaxoSmithKline Trading Services Limited. 
Detailed recommendations for the use of this product are described in the product information (PI), which 
is published in English here. 
The European public assessment report (EPAR) will be published after the marketing authorisation has 
been granted by the European Commission and will make this information available in all official European  
Union languages. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
